Julie Papanek Grant serves as a General Partner at Canaan Partners. See sector focus and contact routes.
Julie Papanek Grant serves as a General Partner at Canaan Partners, where she joined in 2013 after progressing from Associate to Principal before leading the healthcare team. She primarily invests in early-stage biopharmaceutical and digital health startups, focusing on companies that translate scientific discoveries into patient medicines within the United States. Grant typically leads investments and company formation efforts in biopharmaceuticals, though specific check sizes and follow-on behaviors are not publicly detailed in available sources. Her notable portfolio includes Day One Biopharmaceuticals, for which she was Co-Founder and CEO, as well as Synthekine and Nocion Therapeutics, where she was a founding investor. She also advised or observed on the boards of CytomX, Labrys Biologics, Dermira, and Glooko, reflecting deep operational engagement. Grant’s distinctive point of view centers on taming cancer, boosting diversity in healthcare, and expanding consumer access to affordable care, drawing on her prior oncology work at Genentech. She holds an MBA from Stanford, an M.Phil. in BioScience Enterprise from Cambridge, and a B.S. from Yale, c
Details on this investor come from filing and round data held in the StartupFundraising directory, refreshed on ingest. Founders use profiles like this one to qualify fit and to shortlist investors in Menlo Park.
Investors like Julie Papanek Grant · Full investor directory · Investor access · Company funding database